The authors pinpointed intratumoral CD68-positive macrophages, M1 macrophages and intrastromal CD4+ cells, CD4+ FOXP3- cells, CD8+ cells and PD-L1+ cells to be the most robust prognostic biomarkers for DFS in lung cancer [50]. This evidence concerns the gene FOXP3 and lung carcinoma.